Santen Pharmaceutical Co (TSE:4536) Total Liabilities : 円130,330 Mil (As of Mar. 2024)

View and export this data going back to 1964. Start your Free Trial

What is Santen Pharmaceutical Co Total Liabilities?

Santen Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 was 円130,330 Mil.

Santen Pharmaceutical Co's quarterly Total Liabilities increased from Sep. 2023 (円120,530.00 Mil) to Dec. 2023 (円129,836.00 Mil) and increased from Dec. 2023 (円129,836.00 Mil) to Mar. 2024 (円130,330.00 Mil).

Santen Pharmaceutical Co's annual Total Liabilities increased from Mar. 2022 (円123,132.00 Mil) to Mar. 2023 (円127,882.00 Mil) and increased from Mar. 2023 (円127,882.00 Mil) to Mar. 2024 (円130,330.00 Mil).

Santen Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Santen Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Total Liabilities Chart

Santen Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

106,208.00

95,639.00

123,132.00

127,882.00

130,330.00

Santen Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															127,882.00	116,309.00	120,530.00	129,836.00	130,330.00

Santen Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Santen Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	92796	+	(0	+	36242
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	1292)
	=	130,330

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	435699	-	305369
	=	130,330

Santen Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	92796	+	(0	+	36242
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	1292)
	=	130,330

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	435699	-	305369
	=	130,330

Santen Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Santen Pharmaceutical Co (TSE:4536) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (TSE:4536) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SNPHY:USA SNPHF:USA SZD:Germany

Address

Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552

Website

http://www.santen.co.jp

Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (TSE:4536) Headlines

No Headlines